Differential SELEX in human glioma cell lines
Laura Cerchia1, Carla Lucia Esposito, Andreas H Jacobs
1Istituto per l'Endocrinologia e l'Oncologia Sperimentale del CNR G Salvatore, Naples, Italy.
Plos One
|December 4, 2009
Summary
Researchers developed a novel aptamer selection method to identify unique cancer cell signatures. This approach accurately distinguishes tumor types, paving the way for targeted therapies and reduced side effects in oncology patients.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Accurate tumor type distinction is crucial for effective cancer therapy.
- Identifying tumor-specific signatures can predict treatment response and minimize adverse effects.
Purpose of the Study:
- To develop a method for generating high-affinity aptamers targeting cell surface epitopes.
- To create aptamers capable of distinguishing between different glioma cell lines and tumorigenicity levels.
Main Methods:
- Utilized differential whole cell SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for aptamer generation.
- Iteratively evolved random nucleic acid sequences against U87MG glioma cells to isolate specific ligands.
- Selected aptamers designed to differentiate between U87MG and T98G cell lines.
Main Results:
- Successfully generated aptamers with unique binding patterns for identified human glioma cell lines.
- Demonstrated the ability to distinguish high-grade from low-grade or non-tumorigenic cell lines.
- Identified five aptamers that inhibit specific intracellular pathways, suggesting roles in surface signaling.
Conclusions:
- Differential whole cell SELEX is an effective strategy for generating highly specific aptamers against cancer biomarkers.
- The developed aptamers can unequivocally identify and differentiate cancer cell lines.
- This method holds broad applicability for cancer research and therapeutic development.